Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG

Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd., Atlanta, GA 30333, USA.
Journal of immunological methods (Impact Factor: 2.01). 12/2011; 376(1-2):97-107. DOI: 10.1016/j.jim.2011.12.002
Source: PubMed

ABSTRACT Accurate, reliable and standardized quantification of anti-protective antigen (PA) IgG antibody levels is essential for comparative analyses of anti-toxin immune responses in anthrax cases, recipients of PA-based anthrax vaccines and for evaluation of anti-PA based immunotherapies. We have previously reported the early performance characteristics and application of a quantitative anti-PA IgG enzyme linked immunosorbent assay. The principal application of this assay was in a Phase 4 human clinical trial of anthrax vaccine adsorbed (AVA, BioThrax), the central component of the CDC Anthrax Vaccine Research Program (AVRP) and in humans following bioterrorism associated Bacillus anthracis infection (Quinn et al., 2002; Quinn et al., 2004; Marano et al., 2008). The objective of the AVRP was to determine the feasibility of reducing the number of priming series and booster doses of the licensed Anthrax Vaccine Adsorbed (AVA) (BioThrax®; Emergent BioSolutions, Lansing, MI) and changing the route of administration from subcutaneous (SC) to intramuscular (IM) (Marano et al., 2008). In this paper we report the validation and long term performance characteristics of the assay during its six year application in the AVRP (2002-2008). The critical features are 1) extensive validation of the assay using two standard reference sera; 2) long term stability and 3) consistency of the data for quantitative analysis of human long term anti-PA IgG responses. The reportable value (RV) of the assay was expressed as anti-PA IgG concentration (μg/ml). Accuracy of the assay was high with a percent error (%ER) range of 1.6-11.4%. Overall intra-operator and intermediate precision were high with Coefficients of Variation (%CVs) of 2.5-15.4% and 6.3-13.2%, respectively. The assay demonstrated excellent dilutional linearity for human sera using log(10) transformed data with the slope=0.95 to 0.99, intercept=0.02 to 0.06 and r(2)=0.980-0.987. The assay was robust, tolerating changes in serum incubation temperatures from 35 to 39°C, serum incubation times from 55 to 65min and changes in key reagents. The long-term assay stability over 6years using consecutive reference sera AVR414 and AVR801 demonstrated sustained high accuracy and precision for the assay, confirming its suitability for long term studies of PA protein-based anthrax vaccines.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Highly luminescent quantum dot beads (QBs) were synthesized by encapsulating CdSe/ZnS and used for the first time as immunochromatographic assay (ICA) signal amplification probe for ultrasensitive detection of aflatoxin B1 (AFB1) in maize. The challenges to use high brightness QBs as probes for ICA are smooth flow of QBs and non-specific binding on nitrocellulose (NC) which is overcome by unique polymer encapsulation of quantum dots (QDs) and surface blocking method. Under optimal conditions, the QB-based ICA (QB-ICA) sensor exhibited dynamic linear detection of AFB1 in maize extract from 5 pg mL-1 to 60 pg mL-1, with a median inhibitory concentration (IC50) of 13.87 ± 0.16 pg mL-1, that is significantly 39 folds lower than those of the QD as a signal probe (IC50 = 0.54 ± 0.06 ng mL-1). The limit of detection (LOD) for AFB1 using QB-ICA sensor was 0.42 pg mL-1 in maize extract which is approximate two orders of magnitude better than those of previously reported gold nanoparticles based immunochromatographic assay (AuNP-ICA) and is even comparable with or better than the conventional enzyme-linked immunosorbent assay (ELISA) method. The performance and practicability of our QB-ICA sensor were validated with a commercial ELISA kit and further confirmed with liquid chromatography tandem mass spectrometry (LC-MS/MS). Given its efficient signal amplification performance, the proposed QBs-ICA offers great potential for rapid, sensitive, and cost-effective quantitative detection of analytes in food safety monitoring.
    ACS Applied Materials & Interfaces 08/2014; 6(16). DOI:10.1021/am503517s · 5.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Humoral and cell mediated immune correlates of protection (COP) for inhalation anthrax in a rhesus macaque (Macaca mulatta) model were determined. Immunological and survival data were from 114 vaccinated and 23 control animals exposed to Bacillus anthracis spores at 12, 30 or 52 months after the first vaccination. Vaccinated animals received a 3-dose intramuscular priming series (0, 1, 6 months; 3-IM) of anthrax vaccine adsorbed (AVA, BioThrax™). Immune responses were modulated by administering a range of vaccine dilutions. Together with vaccine dilution dose and the interval between first vaccination and challenge, each of 80 immune response variables to anthrax toxin protective antigen (PA) at every available study time point was analyzed as a potential COP by logistic regression penalized by Least Absolute Shrinkage and Selection Operator (LASSO) or elastic net. Anti-PA IgG at the last available time point before challenge ('Last') and lymphocyte stimulation index (SI) at months 2 and 6 were identified consistently as COP. Anti-PA IgG and lethal toxin neutralization activity (TNA) at month 6 and month 7 ('Peak') and the frequency of IFN-γ secreting cells at month 6 also had statistically significant positive correlations with survival. The ratio of IL-4 mRNA to IFN-γ mRNA at month 6 also had a statistically significant correlation with survival. TNA had lower COP accuracy than anti-PA IgG. Following 3-IM priming with AVA, the anti-PA IgG responses at the time of exposure or at month 7 were practicable and accurate metrics for correlating vaccine induced immunity with protection against inhalation anthrax.
    Clinical and vaccine Immunology: CVI 09/2014; 21(11). DOI:10.1128/CVI.00469-14 · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Inhalation anthrax is a rare but acute infectious disease following adsorption of Bacillus anthracis spores through the lungs. The disease has a high fatality rate if untreated, but early and correct diagnosis has a significant impact on case patient recovery. The early symptoms of inhalation anthrax are, however, non-specific and current anthrax diagnostics are primarily dependent upon culture and confirmatory real-time PCR. Consequently, there may be a significant delay in diagnosis and targeted treatment. Rapid, culture-independent diagnostic tests are therefore needed, particularly in the context of a large scale emergency response. The aim of this study was to evaluate the ability of monoclonal antibodies to detect anthrax toxin proteins that are secreted early in the course of B. anthracis infection using a time-resolved fluorescence (TRF) immunoassay. We selected monoclonal antibodies that could detect protective antigen (PA), as PA83 and also PA63 and LF in the lethal toxin complex. The assay reliable detection limit (RDL) was 6.63 x 10(-6)μM (0.551ng/ml) for PA83 and 2.51 x 10(-5)μM (1.58ng/ml) for PA63. Despite variable precision and accuracy of the assay, PA was detected in 9 out of 10 sera samples from anthrax confirmed case patients with cutaneous (n=7), inhalation (n=2), and gastrointestinal (n=1) disease. Anthrax Immune Globulin (AIG), which has been used in treatment of clinical anthrax, interfered with detection of PA. This study demonstrates a culture-independent method of diagnosing anthrax through use of monoclonal antibodies to detect PA and LF in the lethal toxin complex.
    Journal of Immunological Methods 05/2014; DOI:10.1016/j.jim.2014.05.008 · 2.01 Impact Factor


Available from
Mar 3, 2015